Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib mesylate + cyclophosphamide + docetaxel + epirubicin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination regimen consisting of four agents: apatinib mesylate (also known as rivoceranib), cyclophosphamide, docetaxel, and epirubicin. Apatinib mesylate is an orally bioavailable small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting angiogenesis and tumor growth. Cyclophosphamide is an alkylating agent that interferes with DNA replication and transcription, leading to cell death. Docetaxel is a taxane-class chemotherapeutic that stabilizes microtubules and inhibits cell division. Epirubicin is an anthracycline antibiotic that intercalates into DNA, inhibiting topoisomerase II and generating free radicals to induce cytotoxicity. This combination may be used in investigational or off-label settings for advanced cancers where multi-agent chemotherapy plus antiangiogenic therapy may provide synergistic antitumor effects[1][3][6].
- Brand names
- Aitan (for apatinib mesylate)
- Other names
- rivoceranib mesylate + cyclophosphamide + docetaxel + epirubicin
02
Targets
DNA guanine N7 sitesTOP2A (DNA topoisomerase II)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on apatinib mesylate + cyclophosphamide + docetaxel + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib mesylate + cyclophosphamide + docetaxel + epirubicin.